International Urogynecology Journal

, Volume 19, Issue 7, pp 987–990

The effects of intravesical pentosanpolysulfate treatment on the symptoms of patients with bladder pain syndrome/interstitial cystitis: preliminary results

  • Lukas K. Daha
  • Dara Lazar
  • Reiner Simak
  • Heinz Pflüger
Original Article

DOI: 10.1007/s00192-008-0560-8

Cite this article as:
Daha, L.K., Lazar, D., Simak, R. et al. Int Urogynecol J (2008) 19: 987. doi:10.1007/s00192-008-0560-8

Abstract

The objective of the study was to determine whether intravesical pentosanpolysulfate (PPS) reduces symptoms associated with bladder pain syndrome/interstitial cystitis (BPS/IC). In a prospective, uncontrolled, open-label study, 29 female patients with BPS/IC received 300 mg PPS intravesically twice a week for 10 weeks and thereafter a voluntary maintenance therapy once a month. Treatment response was assessed by Visual Analog Scale (VAS) for quality of life and O’Leary–Sant Symptom and Problem Index (OSPI). Patients were tested before treatment, after 5 weeks of treatment, and 1 week, 3, 6, and 12 months after termination of the initial treatment. Twenty-five patients underwent the 10-week treatment and the 3-month follow-up. Mean reduction of VAS/OSPI was from 8.8/26.4 before to 4/15.3 after treatment, 3.8/15.2 after 3 months, 3.8/14 after 6 months, and 3.4/12.1 after 12 months. In 21 patients, renewed instillation or maintenance therapy was necessary. Intravesical treatment with PPS reduces both the VAS and the OSPI in patients with BPS/IC.

Keywords

Bladder Pain Interstitial cystitis Pentosanpolysulfate 

Copyright information

© International Urogynecology Journal 2008

Authors and Affiliations

  • Lukas K. Daha
    • 1
    • 2
  • Dara Lazar
    • 1
    • 2
  • Reiner Simak
    • 1
    • 2
  • Heinz Pflüger
    • 1
    • 2
  1. 1.Ludwig Boltzmann Institute of Urology and AndrologyMunicipal Hospital HietzingViennaAustria
  2. 2.Department of UrologyMunicipal Hospital HietzingViennaAustria

Personalised recommendations